Oasmia Pharmaceutical AB

Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow

Oasmia Pharmaceutical Launches US Brand and Sales Platform

Year-end report for the fiscal year May 2014 – April 2015

Changes in Oasmia’s Board of Directors and Management

Communiqué from Oasmia’s Extraordinary General Meeting 2015

Oasmia gives notice of Extraordinary General Meeting

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB (publ)

Results from Oasmia’s Phase III study will be presented at ASCO

Oasmia’s lead cancer product Paclical(r) receives market approval in the Russian Federation

Oasmia’s lead cancer product Paclical® receives market approval in the Russian Federation

Interim report for the period May 2014 – January 2015

Oasmia initiates clinical Phase II study with Doxophos Vet for the treatment of canine lymphoma

Nxt2b extends loan to Oasmia

Publication of change in the total number of shares and votes in Oasmia

Publication of change in the total number of shares and votes in Oasmia

Oasmia receives a new MSEK 20 bank loan

Oasmia’s Chairman of the Board buys shares

Oasmia change to Mid Cap segment at Nasdaq Stockholm

Final result of Oasmia’s rights issue

Preliminary result of Oasmia’s rights issue

Prospectus addendum regarding Oasmia Pharmaceutical’s rights issue is now available

Interim report for the period May – October 2014

Prospectus, including new financial information, regarding Oasmia Pharmaceutical’s rights issue is now available

Oasmia Pharmaceutical AB announces a fully committed and underwritten rights issue of approximately SEK 176 million.

Oasmia’s lead human oncology product Paclical shows a positive risk/benefit profile versus standard treatment in pivotal phase III clinical study

Communiqué from Oasmia’s Annual General Meeting 2014

Oasmia receives a new MSEK 40 bank loan

Oasmia considers secondary listing on NASDAQ USA

Interim report for the period May – July 2014

Correction of notice regarding notice of Annual General Meeting